TPG GP A LLC lessened its position in Smith & Nephew plc (NYSE:SNN - Free Report) by 69.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 456,206 shares of the medical equipment provider's stock after selling 1,028,575 shares during the quarter. TPG GP A LLC owned approximately 0.10% of Smith & Nephew worth $11,214,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Point72 Asset Management L.P. acquired a new stake in Smith & Nephew in the 4th quarter valued at approximately $6,132,000. Quantinno Capital Management LP raised its position in Smith & Nephew by 83.8% in the 4th quarter. Quantinno Capital Management LP now owns 97,818 shares of the medical equipment provider's stock valued at $2,404,000 after buying an additional 44,592 shares during the last quarter. J. Goldman & Co LP bought a new stake in Smith & Nephew during the fourth quarter worth about $47,700,000. D. E. Shaw & Co. Inc. raised its holdings in Smith & Nephew by 340.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 166,587 shares of the medical equipment provider's stock worth $4,095,000 after acquiring an additional 128,780 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Smith & Nephew during the fourth quarter worth about $1,063,000. Institutional investors and hedge funds own 25.64% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the company. Canaccord Genuity Group upped their target price on Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a report on Thursday, May 1st. Wall Street Zen upgraded Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. UBS Group lowered Smith & Nephew from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. HSBC lowered Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Hsbc Global Res lowered Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $28.00.
Check Out Our Latest Analysis on SNN
Smith & Nephew Stock Performance
Shares of NYSE SNN traded up $0.25 during trading hours on Friday, reaching $28.65. 948,581 shares of the stock were exchanged, compared to its average volume of 800,456. The firm has a market capitalization of $12.55 billion, a price-to-earnings ratio of 13.26, a P/E/G ratio of 1.26 and a beta of 0.68. Smith & Nephew plc has a 52 week low of $23.69 and a 52 week high of $31.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The stock's fifty day simple moving average is $27.43 and its 200 day simple moving average is $26.37.
Smith & Nephew Increases Dividend
The business also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be given a dividend of $0.447 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a yield of 2.5%. This is an increase from Smith & Nephew's previous semi-annual dividend of $0.29. Smith & Nephew's dividend payout ratio is currently 41.20%.
About Smith & Nephew
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Recommended Stories
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
